Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care (SOC) anticancer regimens.
K. K. Sankhala
Research Funding - SuperGen
A. W. Tolcher
Consultant or Advisory Role - Genentech; SuperGen
Research Funding - Genentech; Ortho Biotech; SuperGen
M. M. Mita
Research Funding - SuperGen
M. S. Gordon
Research Funding - SuperGen
L. S. Rosen
Research Funding - SuperGen
K. P. Papadopoulos
Research Funding - SuperGen
A. Patnaik
Research Funding - SuperGen
R. L. Drengler
Research Funding - SuperGen
A. C. Mita
Research Funding - SuperGen
J. Sarantopoulos
No relevant relationships to disclose
R. G. Bristow
Research Funding - SuperGen
G. Fine
Employment or Leadership Position - SuperGen
Stock Ownership - SuperGen
G. S. Choy
Employment or Leadership Position - SuperGen
Stock Ownership - SuperGen
M. Azab
Employment or Leadership Position - SalerGen
Stock Ownership - SuperGen